Effects of rare CYP2C9 alleles on stable warfarin doses in Chinese Han patients with atrial fibrillation

被引：6
|
作者：
Wang, Dongxu [1 ]
Dai, Da-Peng [2 ]
Wu, Hualan [1 ]
Chong, Jia [1 ]
Lu, You [1 ]
Yin, Ruoyun [1 ]
Zhao, Xinlong [1 ]
Zhao, Anxu [1 ]
Yang, Jiefu [1 ]
Chen, Hao [1 ]
机构：
[1] Beijing Hosp, Cardiovasc Dept, Natl Ctr Gerontol, Beijing 100730, Peoples R China
[2] Beijing Hosp, Natl Ctr Gerontol, Key Lab Geriatr, Beijing 100730, Peoples R China
来源：
PHARMACOGENOMICS | 2020年 / 21卷 / 14期
基金：
美国国家科学基金会;
关键词：
atrial fibrillation; gene polymorphism; warfarin-dosing algorithm; warfarin; GENETIC-VARIANTS; IN-VITRO; FUNCTIONAL-CHARACTERIZATION; CYP2C9-ASTERISK-13; ALLELE; GENOTYPE; VKORC1; IDENTIFICATION; REQUIREMENT; PHARMACOKINETICS; ANTICOAGULATION;
D O I：
10.2217/pgs-2020-0051
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Aim:Gene polymorphisms are critical in warfarin dosing variation. Here, the role of rareCYP2C9alleles on warfarin doses in Chinese Han patients was investigated.Methods:A retrospective study recruited 681 warfarin treated atrial fibrillation patients. The genetic and clinical data were collected. Dose-related variables were selected by univariate analyses and the warfarin-dosing algorithm was derived by multivariate regression analysis.Results:Three rareCYP2C9alleles (CYP2C9*13, *16 and *60) were associated with lower stable doses. Inclusion of the rareCYP2C9alleles in the prediction model added an extra 3.7% warfarin dose predictive power.Conclusion:CYP2C9*13, *16 and *60 was associated with lower stable warfarin doses in Chinese patients. The algorithm including rareCYP2C9alleles tends to more accurately predict stable warfarin doses.
引用
收藏
页码：1021 / 1031
页数：11
相关论文
共 50 条
  • [41] CYP2C9 polymorphism analysis in Han Chinese populations: building the largest allele frequency database
    Dai, D-P
    Xu, R-A
    Hu, L-M
    Wang, S-H
    Geng, P-W
    Yang, J-F
    Yang, L-P
    Qian, J-C
    Wang, Z-S
    Zhu, G-H
    Zhang, X-H
    Ge, R-S
    Hu, G-X
    Cai, J-P
    PHARMACOGENOMICS JOURNAL, 2014, 14 (01) : 85 - 92
  • [42] Warfarin maintenance dose associated with genetic polymorphisms of CYP2C9
    Khaleqsefat, E.
    Khalaj-Kondori, M.
    Bonyadi, Jabbarpour M.
    Battaloglu, E.
    HIPPOKRATIA, 2017, 21 (02) : 93 - 96
  • [43] Systematic polymorphism analysis of the CYP2C9 gene in Chinese Han and Tibetan populations
    Wang, Yue-Wen
    Meng, Xiao-Hong
    Yan, Wei
    Zhang, Xiao-Qing
    Yang, Jin
    GENES & GENOMICS, 2012, 34 (03) : 291 - 297
  • [44] Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers
    Shao, H.
    Ren, X. M.
    Liu, N. F.
    Chen, G. M.
    Li, W. L.
    Zhai, Z. H.
    Wang, D. W.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2010, 35 (03) : 351 - 360
  • [45] Variant CYP2C9 alleles and warfarin concentrations in patients receiving low-dose versus average-dose warfarin therapy
    Redman, Andrea R.
    Zheng, Jack
    Shamsi, Shahab A.
    Huo, Jingguo
    Kelly, Edward J.
    Ho, Rodney J. Y.
    Ritchie, Denise M.
    Hon, Yuen Yi
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2008, 14 (01) : 29 - 37
  • [46] Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of zafirlukast
    Lee, Hyun-Jee
    Kim, Young-Hoon
    Kim, Se-Hyung
    Lee, Choong-Min
    Yang, Ae-Yun
    Jang, Choon-Gon
    Lee, Seok-Yong
    Bae, Jung-Woo
    Choi, Chang-Ik
    ARCHIVES OF PHARMACAL RESEARCH, 2016, 39 (07) : 1013 - 1019
  • [47] Resequencing of VKORC1, CYP2C9 and CYP4F2 genes in Italian patients requiring extreme low and high warfarin doses
    Di Fusco, Davide
    Ciccacci, Cinzia
    Rufini, Sara
    Forte, Vittorio
    Novelli, Giuseppe
    Borgiani, Paola
    THROMBOSIS RESEARCH, 2013, 132 (01) : 123 - 126
  • [48] CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients
    M. V. Lima
    G. S. Ribeiro
    E. T. Mesquita
    P. R. Victer
    R. Vianna-Jorge
    European Journal of Clinical Pharmacology, 2008, 64 : 9 - 15
  • [49] First report of warfarin dose requirements in patients possessing the CYP2C9*12 allele
    O'Brien, Travis J.
    Kidd, Robert S.
    Richard, Craig A. H.
    Ha, Ngoc-Han
    Witcher, Preston
    Tran, Linda V.
    Barbour, April
    Tuck, Matthew
    McIntosh, Samantha D.
    Douglas, Jacqueline N.
    Harralson, Arthur F.
    CLINICA CHIMICA ACTA, 2013, 424 : 73 - 75
  • [50] Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9
    Sagrieya, Hersh
    Berube, Caroline
    Wen, Alice
    Ramakrishnan, Ramesh
    Mir, Alain
    Hamilton, Amy
    Altman, Russ B.
    PHARMACOGENETICS AND GENOMICS, 2010, 20 (07) : 407 - 413
12345